Private Trust Co. NA lifted its position in Becton Dickinson and Co (NYSE:BDX) by 12.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,557 shares of the medical instruments supplier’s stock after purchasing an additional 491 shares during the period. Private Trust Co. NA’s holdings in Becton Dickinson and were worth $975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Becton Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares in the last quarter. Harfst & Associates Inc. boosted its position in shares of Becton Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the last quarter. Harvest Fund Management Co. Ltd boosted its position in shares of Becton Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after acquiring an additional 338 shares during the last quarter. Acrospire Investment Management LLC boosted its position in shares of Becton Dickinson and by 259.7% during the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after acquiring an additional 600 shares during the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in shares of Becton Dickinson and during the third quarter worth $191,000. 75.54% of the stock is owned by hedge funds and other institutional investors.

BDX has been the subject of a number of research reports. Royal Bank of Canada restated a “hold” rating and set a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Zacks Investment Research lowered shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Deutsche Bank set a $260.00 target price on shares of Becton Dickinson and and gave the stock a “buy” rating in a research report on Friday, December 29th. Stifel Nicolaus restated a “buy” rating and set a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Morgan Stanley upped their target price on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and has a consensus rating of “Buy” and an average price target of $230.20.

Becton Dickinson and Co (BDX) traded up $1.89 during mid-day trading on Tuesday, reaching $227.71. 1,870,400 shares of the company’s stock traded hands, compared to its average volume of 1,668,844. Becton Dickinson and Co has a fifty-two week low of $169.19 and a fifty-two week high of $229.68. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The company has a market capitalization of $52,530.00, a price-to-earnings ratio of 48.97, a P/E/G ratio of 1.78 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. Becton Dickinson and’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.12 earnings per share. research analysts anticipate that Becton Dickinson and Co will post 10.66 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were issued a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.32%. The ex-dividend date was Thursday, December 7th. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio (DPR) is 64.52%.

COPYRIGHT VIOLATION NOTICE: “Private Trust Co. NA Has $975,000 Stake in Becton Dickinson and Co (BDX)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/01/16/private-trust-co-na-has-975000-stake-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related stocks with our FREE daily email newsletter.